PTC Therap (PTCT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec23

PTC Therapeutics Chief Business Officer Disposes of Company Common Stock

22:15

Dec22

PTC Therapeutics Inc. received Japan Ministry of Health approval for Sephience™

12:02

Dec19

PTC Therapeutics Inc. CCO Reports Common Stock Dispositions

22:20

Dec18

Wells Fargo Maintains Buy Rating for PTC Therapeutics with a Price Target of $93

16:38

Dec10

PTC Therapeutics' Sephience™ Receives Health Canada Approval for PKU Treatment

13:01

Dec5

PTC Therapeutics Director Emma Reeve Reports Common Stock Disposition

22:20

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 211.01 M, Net Income 15.9 M, EPS 0.195

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 178.88 M, Net Income -64.85 M, EPS -0.8299

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 1.176 B, Net Income 866.56 M, EPS 10.04

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change